Maftivimab
Based on 1 Customer Validation
Maftivimab (REGN3470-3471-3479) is a human monoclonal antibody targeting the glycoprotein of Zaire ebolavirus (ZEBOV), with an IC50 of 0.17 nM and a Kd of 2.97 nM. Maftivimab is applicable to research related to Zaire ebolavirus infection and Ebola virus disease.
For research use only. We do not sell to patients.
- Purity : 96.89%
- CAS No.: 2135632-36-7
- Molecular Weight:143.94 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
[1]|
ZEBOV 2.97 nM (Kd) |
ZEBOV 0.17 nM (IC50) |
In Vitro
Maftivimab binds with high affinity to the recombinant histidine-tagged extracellular domain protein of Ebola virus Makona strain glycoprotein (Kd = 2.97 × 10 nM[1]).
Maftivimab potently neutralizes Ebola pseudovirus particles in vitro, with an IC50 of 0.17 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
911829 [NCBI]
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2135632-36-7
-
Appearance Liquid
-
Molecular Weight 143.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Maftivimab]
-
Synonyms
REGN3470-3471-3479
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Markham A. REGN-EB3: First Approval. Drugs. 2021 Jan;81(1):175-178.
[2]. Gaudinski MR, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)